Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Animals
Antineoplastic Agents
/ chemistry
Cell Line, Tumor
Combined Modality Therapy
/ methods
Heterografts
/ drug effects
Humans
Lutetium
/ chemistry
Male
Mice
Mice, Inbred BALB C
Mice, Nude
PC-3 Cells
Polyethylene Glycols
/ chemistry
Prostate
/ drug effects
Prostatic Neoplasms
/ drug therapy
Radioisotopes
/ chemistry
Receptors, Bombesin
/ antagonists & inhibitors
Tissue Distribution
/ physiology
Trastuzumab
/ pharmacology
Tumor Protein, Translationally-Controlled 1
GRPR
HER2
lutetium-177
prostate cancer
radionuclide therapy
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 12 2019
15 12 2019
Historique:
received:
19
01
2019
revised:
19
04
2019
accepted:
02
05
2019
pubmed:
12
5
2019
medline:
31
1
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are suitable for targeted radionuclide therapy (TRT). We optimized the bombesin-derived GRPR-antagonist PEG
Identifiants
pubmed: 31077356
doi: 10.1002/ijc.32401
pmc: PMC6852655
doi:
Substances chimiques
Antineoplastic Agents
0
Radioisotopes
0
Receptors, Bombesin
0
Tpt1 protein, mouse
0
Tumor Protein, Translationally-Controlled 1
0
Polyethylene Glycols
3WJQ0SDW1A
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3347-3358Informations de copyright
© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Cancer Metastasis Rev. 2015 Mar;34(1):157-64
pubmed: 25712293
J Nucl Med. 2010 Jul;51(7):1131-8
pubmed: 20554729
Curr Med Chem. 2010;17(24):2636-55
pubmed: 20491631
Br J Pharmacol. 2006 Feb;147 Suppl 2:S144-52
pubmed: 16465179
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
Bioconjug Chem. 2018 May 16;29(5):1774-1784
pubmed: 29664606
Clin Cancer Res. 2017 Jul 1;23(13):3343-3351
pubmed: 28108545
BioDrugs. 2016 Apr;30(2):75-86
pubmed: 26892619
Oncotarget. 2016 Sep 27;7(39):64447-64470
pubmed: 27487144
J Nucl Med. 1990 Jul;31(7):1191-8
pubmed: 2362198
Contrast Media Mol Imaging. 2017 Aug 10;2017:6873684
pubmed: 29097932
Exp Ther Med. 2011 May;2(3):523-528
pubmed: 22977535
J Nucl Med. 2014 Jan;55(1):121-7
pubmed: 24287321
Prostate. 2009 Jul 1;69(10):1101-8
pubmed: 19343734
J Pept Res. 1999 Mar;53(3):275-83
pubmed: 10231715
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988
pubmed: 29497803
J Med Radiat Sci. 2017 Mar;64(1):52-60
pubmed: 28303694
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
J Natl Cancer Inst. 2000 Dec 6;92(23):1918-25
pubmed: 11106683
J Nucl Med. 2015 Dec;56(12):1809-12
pubmed: 26514175
Molecules. 2014 Jul 17;19(7):10455-72
pubmed: 25036155
Cancer Biother Radiopharm. 2016 Feb;31(1):20-8
pubmed: 26844849
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
Cancer. 1993 Feb 1;71(3 Suppl):1098-109
pubmed: 7679039
J Nucl Med. 2013 May;54(5):762-9
pubmed: 23492884
Cancer Biother Radiopharm. 2014 Nov;29(9):359-67
pubmed: 25286347
Clin Cancer Res. 2009 Aug 15;15(16):5240-9
pubmed: 19671861
Cancer Res. 1999 Mar 1;59(5):1152-9
pubmed: 10070977
Theranostics. 2016 Jan 01;6(1):104-17
pubmed: 26722377
J Urol. 2005 Dec;174(6):2174-7
pubmed: 16280758
Oncol Lett. 2015 Feb;9(2):950-954
pubmed: 25624915
Cancer Biother Radiopharm. 2007 Jun;22(3):438-42
pubmed: 17651052
Nat Med. 1999 Mar;5(3):280-5
pubmed: 10086382
Phys Med Biol. 2004 Oct 7;49(19):4477-91
pubmed: 15552412
J Nucl Med. 2006 Mar;47(3):375-7
pubmed: 16513604
Trends Pharmacol Sci. 2018 Jan;39(1):24-48
pubmed: 29224916
J Nucl Med. 2008 Feb;49(2):318-26
pubmed: 18199616
Int J Oncol. 2016 May;48(5):2124-34
pubmed: 26983776
Radiat Oncol. 2014 Dec 11;9:258
pubmed: 25497220
Nucl Med Biol. 2015 May;42(5):446-454
pubmed: 25684649